Chronic Disease Management

The chronic disease management market encompasses consumers with chronic, complex conditions such as chronic kidney disease, diabetes, and heart disease. The challenges faced in this market are often compounded by the need for social services and supports. For provider organizations and health systems managing consumers with chronic conditions, a significant challenge that remains is addressing the rising cost of care for this population. As a result, payers are focusing on reducing the spend by increasing integrated models of care coordination across medical, behavioural, pharmacy, and social support systems. These new market forces are creating strategic opportunities for provider organizations that are serving this population.

Latest Resources

• Medicare Launches ACCESS Model; Adds Outcome-Based Payments For Technology-Enabled Care For Depression, SUD & Nicotine Addiction
• Advancing Chronic Care With Effective, Scalable Solutions (ACCESS) Model Payment Amounts & Performance Targets Effective Period: July 5, 2026 – December 31, 2027
• Half Of Adults Starting Semaglutide For Weight Loss Stop Within A Year
• GLP-1 Use Among Children Ages 8 To 11 With Obesity Is Low But Rising
• FDA Selects Four Digital Health Companies For TEMPO Pilot; Two Focus On Behavioral Health
• GLP-1 Prescribing Lags Among Adults With Schizophrenia & Diabetes
• GLP-1s Associated With Lower Mortality Among Adults With Serious Mental Illness
• Older Adults Taking 5 Or More Prescription Drugs Had 38% Higher Mortality Risk
• Mend Well Launches Expanded Chronic Condition Management, Extending Surgical Care Into Long-Term Obesity & Hypertension Support
• West Virginia Offers $2 Million To Expand Home Dialysis Access
• Meant Earns LegitScript Certification For Its Online GLP-1 Weight Care Platform
• DaVita Announces New Value-Based Partnership With Humana To Expand Care For Individuals With Chronic Kidney Disease
• Almost 80% Of Young Adults Have Cardiovascular-Kidney-Metabolic Syndrome Risk
• Pediatric Endocrinologist Workforce Capacity Varies Widely By State
• Indiana Medicaid To Cover GLP-1 Obesity Medications Through Federal BALANCE Model

See All

Treating Obesity & Type 2 Diabetes Reduced Kidney Disease By 62%

Participants in a metabolic care program for type 2 diabetes and obesity/overweight had a 36% lower risk of developing chronic kidney disease (CKD) compared to a matched group who received usual care. Participants also had a 43% lower risk of developing CKD stage 3 or higher and a 62% lower risk of developing CKD stage 4 or higher. The study involved the Virta Health Individualized Nutrition Therapy (VINT) program. VINT is a remotely administered metabolic… Read

• Oncology Hospital-At-Home Program Reduced Six-Month Health Care Costs By Over $8,000 Per Consumer
• Neurocrine Biosciences Completes $2.9 Billion Acquisition Of Soleno Therapeutics To Add A Treatment For Prader-Willi Syndrome To Its Portfolio
• The New Age Of Care Coordination: A Discussion With Jeff Smith, Chief Executive Officer Of Bamboo Health
• Moving From Acute To Chronic 
• Amazon Pharmacy Starts $50 GLP-1 Delivery For Medicare Beneficiaries

To sign-up for monthly Chronic Disease Management alerts, you must be signed in to your account.